Evidence map›Paper›PMID 32222278›Full record

ArticleBiochemical and biophysical research communications2020

Incorporation of α-methylated amino acids into Apolipoprotein A-I mimetic peptides improves their helicity and cholesterol efflux potential.

Rafique Islam, Denis O Sviridov, Steven K Drake, Jude Tunyi, Galina Abdoulaeva, Lita A Freeman, Richard W Pastor, Alan T Remaley

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical and biophysical research communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Interplay between CChembiochem : a European journal of chemical biology · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Apolipoprotein mimetics in cancer.Seminars in cancer biology · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rafique IslamLipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Denis O SviridovLipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: sviridovd@nhlbi.nih.gov.
Steven K DrakeCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, 20892, USA.
Jude TunyiLaboratory of Computational Biology National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Galina AbdoulaevaCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA.
Lita A FreemanLipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Richard W PastorLaboratory of Computational Biology National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Alan T RemaleyLipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
National Institutes of Health · USCenter for Biologics Evaluation and Research · USNational Institutes of Health Clinical Center · US

Funding

Computer Simulations of Membranes and BiopolymersZIAHL000340 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI PASTOR, RICHARD WALTER · 2009 to 2025
$29.1M
Development of Apo Mimetic Peptides for the Treatment Cardiovascular DiseaseZIAHL006095 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI REMALEY, ALAN THOMAS · 2010 to 2025
$20.3M
Intramural NIH HHS Z99 HL999999
6 · The paper itself

Abstract

Apolipoprotein A-I (ApoA-I) mimetic peptides are potential therapeutic agents for promoting the efflux of excess cellular cholesterol, which is dependent upon the presence of an amphipathic helix. Since α-methylated Ala enhances peptide helicity, we hypothesized that incorporating other types of α-methylated amino acids into ApoA-I mimetic peptides may also increase their helicity and cholesterol efflux potential. The last helix of apoA-I, peptide 'A' (VLESFKVSFLSALEEYTKKLNT), was used to design peptides containing a single type of α-methylated amino acid substitution (Ala/A

Indexed as

Amino AcidsAmino Acid SequenceAnimalsApolipoprotein A-ICell LineCholesterolDrug DesignHumansMethylationPeptidomimeticsAmino AcidsApolipoprotein A-ICholesterolPeptidomimeticsAlpha-helixAlpha-methyl amino acidsAtherosclerosisCholesterolPeptides

Identifiers

PMID32222278
PMCPMC8482877
OpenAlexW3013563887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.